ADCK1 Antibody

What is ADCK1 and what are its known biological functions?

ADCK1 is a mitochondrial protein that plays crucial roles in regulating mitochondrial dynamics and cristae structure. Research has shown that ADCK1 utilizes YME1-like 1 ATPase (YME1L1) to control optic atrophy 1 (OPA1) and inner membrane mitochondrial protein (IMMT) . In Drosophila, ADCK1 deletion causes severe developmental impairment, leading to premature death before adulthood . ADCK1 knockdown in flies results in defective locomotive activities, structural abnormalities in muscle tissue, decreased mitochondrial membrane potential, reduced ATP production, increased reactive oxygen species (ROS) production, and elevated apoptosis .

More recent studies have identified additional functions of ADCK1 in cancer biology. In colon cancer, ADCK1 interacts with TCF4 (T-cell factor 4) to activate the β-catenin/TCF signaling pathway, promoting cancer cell colony formation and invasion . ADCK1 has also been identified as a potential therapeutic target in osteosarcoma, where its depletion disrupts mitochondrial functions and inhibits tumor growth .

What are the technical specifications of commonly available ADCK1 antibodies?

ADCK1 antibodies are available in various formats with these typical specifications:

This information is based on commercially available ADCK1 antibodies as detailed in the product information .

What are the standard applications of ADCK1 antibodies in research?

ADCK1 antibodies have been employed in several research applications:

• Western blotting: To detect and quantify ADCK1 expression levels in cell and tissue lysates. This has been critical in studies showing ADCK1 upregulation in cancer tissues compared to normal tissues .

• Immunoprecipitation: To study protein interactions, as demonstrated in research identifying ADCK1's interaction with TCF4 in the Wnt/β-catenin pathway .

• Immunofluorescence and immunocytochemistry: To visualize the subcellular localization of ADCK1, particularly its association with mitochondria in various cell types .

• Immunohistochemistry: Used in clinical research to examine ADCK1 expression patterns in cancer specimens, enabling correlation with patient survival data .

• ELISA: For quantitative detection of ADCK1 in research samples .

Each application requires specific optimization parameters, including antibody dilution, incubation conditions, and appropriate controls.

What are the optimal protocols for using ADCK1 antibodies in Western blotting?

For optimal Western blotting results with ADCK1 antibodies, consider the following protocol:

Sample preparation:

• Lyse cells in RIPA buffer supplemented with protease inhibitors

• For mitochondrial-enriched samples, consider subcellular fractionation

• Quantify protein by Bradford assay

• Load 20-50 μg of total protein per lane

Gel electrophoresis and transfer:

• Use 10% SDS-PAGE for good resolution of the ~60 kDa ADCK1 protein

• Transfer to PVDF membrane at 100V for 60-90 minutes in cold transfer buffer

Antibody incubation:

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary ADCK1 antibody at 1:1000 dilution overnight at 4°C

• Wash 3× with TBST, 10 minutes each

• Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

• Wash 3× with TBST, 10 minutes each

Detection and controls:

• Use enhanced chemiluminescence detection system

• Include positive control (cell line with known ADCK1 expression, such as SW620)

• Include negative control (ADCK1 knockdown or knockout sample)

• Use β-actin or GAPDH as loading control for whole cell lysates

• Use VDAC or other mitochondrial protein as control for mitochondrial fractions

This protocol has been effective in studies examining ADCK1 expression in cancer cells and tissues .

How can ADCK1 antibodies be used to study mitochondrial dynamics?

ADCK1 antibodies can be employed in several methodological approaches to study mitochondrial dynamics:

Immunofluorescence co-localization studies:

• Seed cells on coverslips and grow to 70% confluence

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 for 10 minutes

• Block with 3% BSA for 30 minutes

• Co-stain with ADCK1 antibody (1:200) and mitochondrial markers (MitoTracker or TOMM20 antibody)

• Analyze using confocal microscopy to assess:

  • ADCK1 localization to mitochondria

  • Mitochondrial morphology (fragmented vs. tubular network)

  • Effects of ADCK1 manipulation on mitochondrial network

Protein interaction studies:

• Perform co-immunoprecipitation with ADCK1 antibodies to pull down interacting partners

• Analyze interactions with YME1L1, OPA1, and IMMT by Western blotting

• Examine how these interactions change under different conditions (e.g., mitochondrial stress)

Studies have shown that ADCK1 overexpression induces mitochondrial fission and clustering while disrupting cristae structure in both Drosophila and mammalian cells . This approach allows for detailed analysis of ADCK1's role in maintaining mitochondrial morphology and function.

What validation controls are essential when working with ADCK1 antibodies?

Proper validation controls are critical for ensuring reliable results when working with ADCK1 antibodies:

Positive controls:

• Cell lines with confirmed ADCK1 expression (e.g., colon cancer cell lines SW620 and RKO)

• Tissues known to express ADCK1

• Recombinant ADCK1 protein (if available)

Negative controls:

• ADCK1 knockout samples created using CRISPR/Cas9

• ADCK1 knockdown samples using validated siRNA or shRNA

• Secondary antibody-only controls to assess non-specific binding

• IgG controls for immunoprecipitation experiments

Expression manipulation controls:

• Compare samples with ADCK1 overexpression

• Include time-course experiments following ADCK1 manipulation

• Validate phenotypic changes (e.g., mitochondrial function, apoptosis) following ADCK1 knockdown

Cross-validation approaches:

• Use multiple antibodies targeting different ADCK1 epitopes

• Correlate protein detection with mRNA expression data

• Use tagged ADCK1 constructs as additional controls

In studies of ADCK1's role in mitochondrial function, researchers validated their findings by showing that ADCK1 knockdown decreased mitochondrial membrane potential and ATP production while increasing ROS and apoptosis, effects that could be partially rescued by overexpression of ROS scavengers or apoptosis inhibitors .

How can ADCK1 antibodies be used to investigate the role of ADCK1 in cancer?

ADCK1 antibodies enable several sophisticated approaches to investigate its role in cancer:

Expression analysis in clinical specimens:

• Perform immunohistochemistry on tumor microarrays using ADCK1 antibodies

• Compare expression between tumor and adjacent normal tissues

• Correlate expression levels with clinical parameters and patient survival

This approach has revealed increased ADCK1 expression in colon cancer specimens and animal models, with negative correlation between ADCK1 expression and patient survival .

Functional studies:

• Use ADCK1 antibodies to confirm protein depletion after knockdown or knockout

• Analyze effects on cancer cell phenotypes (proliferation, colony formation, invasion)

• Examine changes in mitochondrial function following ADCK1 manipulation

Research has demonstrated that ADCK1 upregulation promotes cancer cell colony formation and infiltration, while downregulation inhibits these processes along with in vivo tumorigenesis and organoid formation .

Mechanistic investigations:

• Use co-immunoprecipitation with ADCK1 antibodies to identify interacting partners

• Analyze ADCK1's role in specific signaling pathways (e.g., β-catenin/TCF pathway)

• Examine how ADCK1 depletion affects mitochondrial functions in cancer cells

Studies have shown that ADCK1 interacts with TCF4 to activate the β-catenin/TCF signaling pathway in colon cancer and that ADCK1 depletion disrupts mitochondrial functions in osteosarcoma cells, causing mitochondrial membrane potential reduction, ATP depletion, and ROS production .

What approaches can be used to study ADCK1's interaction with YME1L1 and OPA1?

Investigating ADCK1's interactions with YME1L1 and OPA1 requires specialized techniques:

Co-immunoprecipitation studies:

• Prepare cell lysates under mild conditions to preserve protein-protein interactions

• Immunoprecipitate with ADCK1 antibodies

• Probe Western blots for YME1L1 and OPA1

• Perform reciprocal co-IPs with YME1L1 and OPA1 antibodies

• Include appropriate controls (IgG, input samples)

Analysis of OPA1 processing:

• Use Western blotting to detect both long (L-OPA1) and short (S-OPA1) forms

• Examine how ADCK1 manipulation affects the L-OPA1/S-OPA1 ratio

• Investigate the role of YME1L1 in this process

Research has established that ADCK1 utilizes YME1L1 to control OPA1 and IMMT in regulating mitochondrial dynamics and cristae structure . The balance between L-OPA1 and S-OPA1 is regulated by changing the cleavage pattern of OPA1 by YME1L1, and disturbance in this balanced state causes mitochondrial dysfunction and fragmentation .

Functional validation:

• Perform knockdown experiments targeting ADCK1, YME1L1, or OPA1

• Analyze effects on mitochondrial morphology and function

• Conduct rescue experiments to confirm specificity of observed phenotypes

Studies have shown similar phenotypes upon knockdown of these different components, supporting their functional relationship in a common pathway .

How can ADCK1 antibodies help investigate the role of ADCK1 in the β-catenin/TCF signaling pathway?

ADCK1 antibodies enable detailed investigation of ADCK1's role in the β-catenin/TCF pathway:

Protein complex analysis:

• Perform co-immunoprecipitation using ADCK1 antibodies

• Probe for β-catenin and TCF4 in the immunoprecipitates

• Conduct reverse co-IP with TCF4 antibodies

• Analyze how these interactions change under different conditions

Research has demonstrated that ADCK1 interacts with TCF4 in the Wnt/β-catenin signaling pathway, as shown by GST pulldown and co-IP experiments .

Functional analysis:

• Manipulate ADCK1 expression (overexpression or knockdown)

• Use ADCK1 antibodies to confirm expression changes

• Analyze effects on β-catenin/TCF complex formation

• Examine downstream effects on target gene expression and cellular phenotypes

Studies have shown that ADCK1 promotes the interaction of β-catenin and TCF4, while knockdown of ADCK1 inhibits this interaction .

Clinical correlation:

• Analyze ADCK1 and β-catenin expression in patient samples

• Correlate expression patterns with clinical outcomes

• Stratify patients based on combined ADCK1 and β-catenin expression levels

Analysis of patient data has indicated that in cohorts with lower β-catenin expression, higher ADCK1 expression correlates with poorer survival .

What are common technical issues when using ADCK1 antibodies and how can they be resolved?

When working with ADCK1 antibodies, researchers may encounter several challenges:

High background in Western blots:

• Problem: Non-specific bands or general background staining

• Solutions:

  • Increase blocking time (2 hours) or concentration (5-10% milk/BSA)

  • Optimize primary antibody dilution (try 1:2000 instead of 1:1000)

  • Increase washing duration and frequency (5 washes × 5 minutes)

  • Use alternative blocking agents (casein-based blockers)

  • For polyclonal antibodies, consider pre-absorption with non-specific proteins

Weak or no signal:

• Problem: Inability to detect ADCK1 despite expected expression

• Solutions:

  • Increase protein loading (50-75 μg)

  • Reduce antibody dilution (1:500 instead of 1:1000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use more sensitive detection systems (high-sensitivity ECL substrates)

  • For tissue sections, optimize antigen retrieval methods

  • Consider tissue/sample-specific extraction protocols to better preserve ADCK1

Multiple bands or unexpected molecular weight:

• Problem: Detection of bands at unexpected sizes

• Solutions:

  • Verify expected molecular weight (approximately 60 kDa)

  • Include ADCK1 knockdown controls to identify specific bands

  • Consider post-translational modifications or isoforms

  • Use fresh samples with additional protease inhibitors

  • Optimize sample preparation and denaturing conditions

Inconsistent immunofluorescence results:

• Problem: Variable staining patterns or localization

• Solutions:

  • Standardize fixation conditions (duration, temperature)

  • Optimize permeabilization (try 0.1% instead of 0.2% Triton X-100)

  • Use freshly prepared fixatives

  • Include co-staining with mitochondrial markers

  • Consider cell-type specific protocols

How to interpret contradictory ADCK1 expression data across different experimental systems?

When faced with inconsistent ADCK1 expression data across different models or experimental conditions, consider these analytical approaches:

Systematic validation:

• Verify antibody specificity in each model system separately

• Use multiple detection methods (Western blot, qPCR, immunofluorescence)

• Include appropriate positive and negative controls

• Consider using multiple antibodies targeting different ADCK1 epitopes

Biological variables to consider:

• Cell/tissue-specific expression patterns of ADCK1

• Developmental stage differences (particularly important in Drosophila studies )

• Subcellular distribution differences affecting detection efficiency

• Stress conditions that might alter expression or localization

• Post-translational modifications affecting antibody recognition

Technical considerations:

• Differences in protein extraction efficiency across tissues/organisms

• Variations in antibody affinity across species

• Detection method sensitivity limitations

• Sample preparation and handling differences

Integration strategies:

• Focus on relative changes rather than absolute values

• Correlate expression with functional readouts (mitochondrial function, cancer phenotypes)

• Consider context-dependent roles of ADCK1 in different systems

• Use orthogonal approaches to validate key findings

Studies of ADCK1 in different systems have revealed both common and distinct functions. In Drosophila, ADCK1 is critical for development and mitochondrial function , while in human cancer cells, it plays roles in both mitochondrial regulation and signaling pathway activation .

What approaches can validate the specificity of ADCK1 antibodies?

Validating ADCK1 antibody specificity requires a multi-faceted approach:

Genetic manipulation controls:

• CRISPR/Cas9-mediated ADCK1 knockout cells or tissues

• siRNA or shRNA-mediated ADCK1 knockdown

• Analysis of multiple independent knockdown constructs

Research has validated ADCK1 antibody specificity by demonstrating reduced signal in ADCK1 knockout and knockdown samples .

Biochemical validation:

• Peptide competition assays (pre-incubating antibody with immunizing peptide)

• Testing against recombinant ADCK1 protein

• Immunoprecipitation followed by mass spectrometry identification

Orthogonal validation:

• Correlation of protein detection with mRNA expression

• Comparison of multiple antibodies targeting different ADCK1 epitopes

• Parallel analysis with tagged ADCK1 constructs

Functional validation:

• Correlation of antibody signal with expected phenotypes

• Rescue experiments with ADCK1 re-expression

• Cross-species validation when appropriate

Studies have shown consistent results using multiple approaches to validate ADCK1 function, such as demonstrating that both genetic knockout and RNAi-mediated knockdown of ADCK1 produce similar phenotypes in terms of mitochondrial dysfunction and apoptosis induction .

What emerging technologies might enhance ADCK1 antibody applications in research?

Several emerging technologies could advance ADCK1 research using antibodies:

Advanced microscopy techniques:

• Super-resolution microscopy (STED, STORM) for detailed mitochondrial localization

• Live-cell imaging with cell-permeable ADCK1 nanobodies

• Correlative light and electron microscopy (CLEM) to link ADCK1 localization with ultrastructural features

• Light-sheet microscopy for 3D visualization in organoids and tissue samples

Proximity-based proteomics:

• BioID or APEX2 tagging of ADCK1 to identify proximal interacting partners

• Proximity ligation assays to visualize ADCK1 interactions in situ

• Split-GFP complementation to visualize dynamic interactions

Single-cell approaches:

• Single-cell Western blotting for heterogeneity analysis

• Mass cytometry (CyTOF) with ADCK1 antibodies for high-dimensional analysis

• Single-cell proteomics to correlate ADCK1 with other proteins at individual cell level

In vivo applications:

• Intravital microscopy with fluorescently labeled ADCK1 antibody fragments

• Antibody-based biosensors to monitor ADCK1 activity in real-time

• ADCK1 targeting for theranostic applications in cancer

These advanced techniques would build upon established research showing ADCK1's roles in mitochondrial dynamics and cancer progression .

How might ADCK1 antibodies contribute to therapeutic development for ADCK1-associated diseases?

ADCK1 antibodies could play significant roles in therapeutic development:

Target validation and patient stratification:

• Use ADCK1 antibodies to identify and quantify ADCK1 expression in patient samples

• Stratify patients based on ADCK1 expression levels for clinical trials

• Correlate ADCK1 expression with response to therapy

Research has already demonstrated higher ADCK1 expression in cancer tissues and correlation with poor survival , suggesting its potential as a biomarker.

Companion diagnostics:

• Develop immunohistochemistry-based assays to guide treatment decisions

• Monitor ADCK1 expression changes during treatment

• Identify resistance mechanisms involving ADCK1

Therapeutic antibody development:

• Engineer antibodies targeting extracellular regions of ADCK1 (if accessible)

• Develop antibody-drug conjugates for targeted delivery to ADCK1-expressing cancer cells

• Create intrabodies or cell-penetrating antibody fragments targeting ADCK1

Mechanistic research for drug development:

• Use ADCK1 antibodies to screen for compounds that modulate ADCK1 expression or function

• Investigate drug effects on ADCK1-dependent pathways

• Study resistance mechanisms involving ADCK1

Studies have shown that ADCK1 depletion inhibits cancer cell growth and increases sensitivity to chemotherapy , suggesting it as a promising therapeutic target.

What are the key unanswered questions about ADCK1 function that antibodies could help address?

Several fundamental questions about ADCK1 remain to be addressed with antibody-based approaches:

Enzymatic activity and regulation:

• Does ADCK1 function as an active kinase, and if so, what are its substrates?

• What post-translational modifications regulate ADCK1 activity?

• How is ADCK1 expression and localization regulated under different conditions?

Tissue-specific functions:

• Why does ADCK1 knockdown in Drosophila cause tracheal defects ?

• How do ADCK1 functions differ across tissue types in mammals?

• What explains the developmental defects observed in ADCK1-deficient organisms?

Pathway integration:

• How does ADCK1 integrate mitochondrial function with nuclear signaling pathways?

• Does ADCK1 serve as a mitochondrial stress sensor?

• How does ADCK1 interact with other mitochondrial quality control mechanisms?

Disease relevance beyond cancer:

• Is ADCK1 dysfunction involved in mitochondrial diseases?

• Could ADCK1 play roles in neurodegenerative disorders with mitochondrial components?

• Is ADCK1 involved in metabolic disorders or aging processes?